Picton Mahoney Asset Management Invests $7.49 Million in Elanco Animal Health Incorporated $ELAN

Picton Mahoney Asset Management purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 372,140 shares of the company’s stock, valued at approximately $7,494,000. Picton Mahoney Asset Management owned approximately 0.07% of Elanco Animal Health at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ELAN. SJS Investment Consulting Inc. raised its position in Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after buying an additional 1,333 shares during the last quarter. Huntington National Bank boosted its holdings in shares of Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after acquiring an additional 1,087 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Elanco Animal Health by 79.3% in the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after acquiring an additional 951 shares during the period. Finally, Fifth Third Bancorp raised its holdings in shares of Elanco Animal Health by 3,018.3% during the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock valued at $58,000 after purchasing an additional 2,807 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $24.47 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. The stock has a 50-day simple moving average of $24.40 and a two-hundred day simple moving average of $21.94. The firm has a market capitalization of $12.17 billion, a PE ratio of -50.98, a P/E/G ratio of 3.17 and a beta of 1.83. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $27.72.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The business’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.14 earnings per share. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analysts Set New Price Targets

ELAN has been the topic of several research reports. KeyCorp raised their target price on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Leerink Partners raised their price target on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 24th. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $24.00 to $30.00 in a report on Thursday, January 22nd. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Finally, UBS Group raised their target price on Elanco Animal Health from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Insider Activity

In other news, Director Lawrence Erik Kurzius purchased 10,000 shares of the stock in a transaction on Friday, December 12th. The shares were acquired at an average price of $21.30 per share, with a total value of $213,000.00. Following the completion of the acquisition, the director directly owned 131,773 shares of the company’s stock, valued at $2,806,764.90. This trade represents a 8.21% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Jeffrey N. Simmons acquired 22,000 shares of Elanco Animal Health stock in a transaction dated Thursday, December 11th. The stock was purchased at an average cost of $21.75 per share, with a total value of $478,500.00. Following the completion of the purchase, the chief executive officer owned 167,000 shares of the company’s stock, valued at approximately $3,632,250. This represents a 15.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 43,450 shares of company stock worth $937,883 over the last ninety days. Company insiders own 0.89% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.